Cara Therapeutics Inc (NASDAQ:CARA) shares traded 56.01% higher at $0.41 on Wall Street last session.
CARA stock price is now 41.94% away from the 50-day moving average and -12.16% away from the 200-day moving average. The market capitalization of the company currently stands at $22.43M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $6 to $1, Stifel Downgraded its rating from Buy to Hold for Cara Therapeutics Inc (NASDAQ: CARA). , while ‘H.C. Wainwright’ rates the stock as ‘Neutral’
In other news, Posner Christopher, PRESIDENT AND CEO sold 3,668 shares of the company’s stock on Nov 04 ’24. The stock was sold for $1,064 at an average price of $0.29. Upon completion of the transaction, the PRESIDENT AND CEO now directly owns 168,768 shares in the company, valued at $69194.88. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 01 ’24, PRESIDENT AND CEO Posner Christopher sold 4,149 shares of the business’s stock. A total of $1,452 was realized by selling the stock at an average price of $0.35. This leaves the insider owning 172,436 shares of the company worth $70698.76. A total of 16.56% of the company’s stock is owned by insiders.
During the past 12 months, Cara Therapeutics Inc has had a low of $0.23 and a high of $1.15. As of last week, the company has a debt-to-equity ratio of 61.97, a current ratio of 4.77, and a quick ratio of 4.71. The fifty day moving average price for CARA is $0.28516 and a two-hundred day moving average price translates $0.46845 for the stock.
The latest earnings results from Cara Therapeutics Inc (NASDAQ: CARA) was released for 2024-06-30. The net profit margin was -1099.76% and return on equity was -221.25% for CARA. The company reported revenue of $2.56 million for the quarter, compared to $4.87 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -47.47 percent.
